Menu & Search
           1904556600
Speak to our friendly team
Contact Us Now

The UK Watchdog Competition and Markets Authority (CMA) has accused four pharmaceutical firms of breaking competition law by colluding to hike the price of a cancer drug.

700% increase in the price of a cancer drug

The price of the drug, prochlorperazine, was found to have increased by 700% over a period of four years, costing the NHS millions. The drug is often prescribed to cancer patients undergoing chemotherapy, to treat dizziness and nausea.

The CMA claims that UK-based groups Alliance, Focus, Lexon and Medreich unlawfully agreed not to compete over the supply of the drug prochlorperazine to the NHS between June 2013 and July 2018.

As a result, the price of the drug rose from £6.49 for a pack of 50 tablets to £51.68, and the annual cost to the NHS of supplying the drug to patients increased from £2.7m in 2014 to £7.5m in 2018, despite fewer packs being prescribed.

One of the companies, Alliance, released a statement saying that it had “no involvement in the pricing or distribution of prochlorperazine since 2013, when it was out-licensed by the company to Focus Pharmaceuticals on an exclusive basis as is normal market practice”.

They added that they have “not had control of or influence on, and nor has it benefited from, any price increases” and that the group “strongly condemns anti-competitive practices.”

The CMA found that Lexon and Medreich were paid a share of the profits earned by Focus Pharmacy on the supply of the Alliance product, and in return agreed not to compete for the supply in the UK of prochlorperazine.

The watchdog alleges that the four companies entered into an agreement that was implemented through two separate pacts — one between Alliance and Focus, and one between Focus, Lexon and Medreich.

Alliance supplied prochlorperazine exclusively to Focus. Focus then paid Lexon a share of the profits it earned on the onward sales of Alliance’s prochlorperazine. Lexon, in turn, shared these payments with Medreich.

Ann Pope, CMA Senior Director of Antitrust, said: “Agreements where a company pays a rival not to enter the market can lead to higher prices and deprive the NHS of huge savings that often result from competition between drug suppliers.”

She added, “The NHS should not be denied the opportunity of benefitting from an increased choice of suppliers, or lower prices, for important medicine.”

A 2016 investigation by The Times named Alliance as one of the pharmaceutical companies exploiting a loophole in competition law to increase the price of drugs by up to 12,500%, costing the NHS an extra £262m a year.

A time of increased concern

The news comes at a time of increased concern that NHS patients may lose out on vital treatments due to competitive pricing making drugs financially inaccessible.

Last week, MP for Hull East Karl Turner debated the issue in Parliament after a seven-year-old boy wrote to the Prime Minister asking for help getting the price of a potentially life-saving drug reduced. The drug, Orkambi, would help reduce the decline in his lung function caused by cystic fibrosis. Orkambi, marketed by American pharmaceutical company Vertex, is priced at £104,000 for a year’s treatment. After failing to negotiate the price, the NHS determined they were unable to meet this cost.

MP Karl Turner called the extortionate pricing of medicine “a perfect example of predatory capitalism.”

Start Your Claim Today1904556600
Tell us about your case

Just send us a little bit about yourself and your claim and we will respond within 24 hours.

    Get In Touch
    Latest News

    Victims can still sue Ian Paterson

    Ian Patterson jailed In 2017, breast Surgeon, Ian Paterson was jailed for wounding with intent. He had treated thousands of patients in his 14-year […]

    Read More

    Updates to the Civil Procedure Rules – April 2021

    Updates to the Civil Procedure Rules will come into effect on 6 April 2021. In this article, Jonathan Gray highlights some of the key […]

    Read More

    Vulnerable Parties and Witnesses – CPR Update April 2021

    On 6 April 2021 an update to the Civil Procedure Rules will help vulnerable parties and witnesses to navigate litigation. The new rules acknowledge […]

    Read More

    Take a look back through our complete news archive

    Follow us on Twitter

    Being injured by a defective medical product is rare, making it all the more difficult to know what you need to do.

    One of our specialist solicitors Tamlin Bolton, has prepared a guide in case you ever find yourself in this unfortunate position.

    https://bit.ly/2qP3fBr

    Return to crowded A&Es and long ambulance delays will put patients at risk, warn experts https://www.independent.co.uk/news/health/nhs-emergency-hospital-ambulance-delays-b1830061.html?utm_content=Echobox&utm_medium=Social&utm_source=Twitter#Echobox=1618266495

    Load More...